Home » Stocks » OYST

Oyster Point Pharma, Inc. (OYST)

Stock Price: $22.40 USD 1.32 (6.26%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 579.45M
Revenue (ttm) n/a
Net Income (ttm) -68.01M
Shares Out 25.80M
EPS (ttm) -21.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $22.40
Previous Close $21.08
Change ($) 1.32
Change (%) 6.26%
Day's Open 21.03
Day's Range 20.50 - 22.52
Day's Volume 58,680
52-Week Range 16.28 - 40.96

More Stats

Market Cap 579.45M
Enterprise Value 365.84M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 25.80M
Float n/a
EPS (basic) 6.34
EPS (diluted) -21.22
FCF / Share -2.11
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 785,864
Short Ratio 14.86
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.69
Revenue n/a
Operating Income -68.91M
Net Income -68.01M
Free Cash Flow -54.31M
Net Cash 213.61M
Net Cash / Share 8.26
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -29.04%
ROE -48.48%
ROIC 1,606.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(171.21% upside)
Current: $22.40
Target: 60.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-47.30-16.74-5.68
Net Income-45.71-16.50-6.60
Shares Outstanding4.591.411.41
Earnings Per Share-9.97-11.69-13.56
Operating Cash Flow-40.82-17.08-4.67
Capital Expenditures-0.20--
Free Cash Flow-41.02-17.08-4.67
Cash & Equivalents1395.2322.31
Total Debt0.810.06-
Net Cash / Debt1385.1722.31
Book Value137-38.24-21.89
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oyster Point Pharma, Inc.
Employees 30

Stock Information

Ticker Symbol OYST
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: OYST
IPO Date October 31, 2019


Oyster Point Pharma, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.